SUPERNEWS - NYSE:GSK (GSK plc) Stock Price, News, Quote, History

SUPERNEWS

SUPERNEWS

Equities

Top Stories

GSK, Haleon 잔여지분 16억달러 매각…총 40억파운드 확보

5/17, 03:11 EDT

GSK Receives Upgrade to Buy, Ferrari Downgraded to Sell

GSK Upgraded on Vaccine Growth Prospects; Ferrari Downgraded Due to Valuation Concerns

잔탁 발암 논란, 제약사 450억달러 손실 위기

GSK faces critical Zantac ruling amid $45 billion liability concerns, affecting 80,000 plaintiffs and market values.

4/24, 08:31 EDT

Analysts Upgrade GSK and Nvidia with Positive Outlooks

Citi upgrades GSK to 'buy' with a £21 target; UBS raises Nvidia's target to $850, highlighting strong AI demand.

2/13, 06:01 EST

Aiolos Bio Buyout: GSK's Respiratory Market Play

<img src="https://cdn.tickerbell.ai/article/img/9e6bcfb91bdd-4727-9044-246f5be5ae49.png" alt="article-main-img" class="article-img" /> ## Key Takeaway ```GSK acquires Aiolos Bio for up to $1.4 billion, aiming to enhance its respiratory biologics portfolio and address unmet needs in severe asthma treatment.``` ## GSK Acquires Aiolos Bio for Expansion - GSK announces the acquisition of Aiolos Bio for up to $1.4 billion, including a Phase 2-ready antibody called AIO-001 targeting adult patients with specific respiratory and inflammatory conditions. - The deal aims to expand GSK's current respiratory biologics portfolio to reach severe asthma patients with low type 2 inflammation where treatment options are still needed. - Chief Scientific Officer Tony Wood highlights the potential of the portfolio addition to address unmet needs in respiratory and inflammatory conditions. ## Milestone-Based Payment Structure - The additional payment of up to $400 million is contingent on certain regulatory milestones being achieved, indicating confidence in the potential success and regulatory approval of AIO-001. - This milestone-based structure aligns incentives between GSK and Aiolos Bio, ensuring that both parties work towards achieving key developmental goals for the antibody. ## Strategic Implications for Growth - The acquisition reflects GSK's strategic focus on expanding its presence in the respiratory and inflammatory conditions market, aiming to address unmet medical needs through innovative treatments. - With this move, GSK seeks to strengthen its position as a leader in providing solutions for various respiratory diseases while also diversifying its product pipeline. ## STREET VIEWS - Tony Wood, GSK Chief Scientific Officer (Neutral): > "The portfolio addition could expand the reach of our current respiratory biologics portfolio, to the 40% of severe asthma patients with low type 2 inflammation where treatment options are still needed." <div style="display: flex; flex-direction: row;" class="divbox"> <a style="display: flex; flex-direction: row;" class="MuiButtonBase-root wallstreet-review-item" href="https://www.wsj.com/finance/investing/gsk-buys-aiolos-bio-for-up-to-1-4-bln-4eaf44d0" target="_blank" rel="noopener noreferrer"> <div style="font-family: monospace; display: flex; ">  [1]  </div> <span> GSK Buys Aiolos Bio for Up to $1.4 Bln    </span> <span class="MuiTouchRipple-root"></span> </a> </div><div style="display: flex; flex-direction: row;" class="divbox"> <a style="display: flex; flex-direction: row;" class="MuiButtonBase-root wallstreet-review-item" href="https://www.tipranks.com/news/article/lightning-could-strike-twice-for-biotech-penny-stock-chimerix-nasdaqcmrx" target="_blank" rel="noopener noreferrer"> <div style="font-family: monospace; display: flex; ">  [2]  </div> <span> Lightning Could Strike Twice for Biotech Penny Stock Chimerix (NASDAQ:CMRX)    </span> <span class="MuiTouchRipple-root"></span> </a> </div>

GSK, Haleon 잔여지분 16억달러 매각…총 40억파운드 확보

5/17, 03:11 EDT

GSK Receives Upgrade to Buy, Ferrari Downgraded to Sell

잔탁 발암 논란, 제약사 450억달러 손실 위기

4/24, 08:31 EDT

GSK News

애널리스트들, JD.com 비중확대·듀폰 30% 상승 전망

5/17, 06:09 EDT

GSK, Haleon 잔여지분 16억달러 매각…총 40억파운드 확보

5/17, 03:11 EDT

글래스루이스, 엑손 장애물에도 불구하고 체브론-헤스 530억달러 인수 권고

5/17, 00:02 EDT

Figma, 12.5조원 평가 받아 직원주식 매각

5/16, 15:09 EDT

빅테크 11조 달러 랠리에 Druckenmiller·Tepper, 포트폴리오 조정

5/16, 10:54 EDT

화이자, 잔탁 소송 1만건 2억5천만달러 합의

5/16, 00:17 EDT

나이지리아 경제난에 Microsoft, 라고스 엔지니어링센터 폐쇄

광둥홀딩스, GLP 차이나 지분 인수 검토…69억달러 평가

4/30, 01:46 EDT

노보노디스크 웨고비 실적 기대감에 주목

4/26, 05:23 EDT

잔탁 발암 논란, 제약사 450억달러 손실 위기

4/24, 08:31 EDT

연준 선호 인플레이션 지표 완화세, 시장 오판?

4/19, 07:55 EDT

나이지리아 화폐가치 하락에 하이네켄 현지법인 2공장 폐쇄

4/17, 09:02 EDT

LME 지수, 글로벌 주식 1.7% 상회하며 활황

4/12, 23:26 EDT

파라마운트, 스카이댄스와 50억달러 규모 합병 협상

금리인하 기대감에 FTSE 100 사상 최고치 돌파

일본 거래소, 100% 상승세로 글로벌 동료들 압도

3/31, 19:43 EDT

로버트 웜즐리 제독 비극적 사망, 가족 분쟁 및 미해결 의문 드러나

3/31, 05:52 EDT

UBS Unveils High Conviction Picks with 90% Upsides

3/19, 19:33 EDT

Nigeria's Naira Plummets 70%, Economic Reforms Tested

Undervalued Stocks Like Johnson & Johnson and Alphabet Recommended Amid Market Highs

GSK Receives Upgrade to Buy, Ferrari Downgraded to Sell

Are GRANOLAS Stocks the Future of European Market Leadership?

2/29, 18:55 EST

Global Equity Fund Outperforms S&P 500 by 31% in 2023 with Contrarian Strategy

2/28, 18:52 EST

- The chart illustrates a declining trend in the n

2/28, 06:57 EST

Morningstar Spots Bargains: Kraft Heinz, Medtronic, GSK Shine

2/19, 19:45 EST

Analysts Upgrade GSK and Nvidia with Positive Outlooks

2/13, 06:01 EST

European GRANOLAS Match Tech Titans in Market Performance, Offering Lower Volatility and Attractive Valuation

2/12, 04:41 EST

Bristol Myers' Earnings Beat Sparks Future Growth Optimism

Aiolos Bio Buyout: GSK's Respiratory Market Play

Most Read

Ask

Finance

GPT

Beta

Most asked from this Article

summarize today's market

Should I invest in long-term bonds?